StockUS listing USBSEMOTCQBHealthcareQuality Compounder

Biostem Technologies Inc(BSEM) Stock Analysis | Healthcare

USD --+0.00%
Reward73High
Risk27Low
75%Data
Thin -14% profit margin · Revenue down 90% YoY
USD —+0.00 (+0.00%) Previous close · OTCQB
Market cap 76.52M
Reward Ratingⓘ73 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ27 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BSEM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Biostem Technologies Inc?

engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

AI Brief Pro

The brief on Biostem Technologies Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Biostem Technologies Inc?

engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 76.52M, and a P/E ratio of 5.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (73)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio5.1682
Beta0.178
Insider Activity
12M windowNo data
No insider activity data available for this ticker.